Renaissance Technologies
VRDN icon

Renaissance Technologies’s Viridian Therapeutics VRDN Stock Holding History

Renaissance Technologies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
768,600
+565,500
+278% +$9.11M 0.02% 876
2026
Q1 		$3.97M Buy
+203,100
New +$6.03M 0.01% 1501
2025
Q2 		– Sell
-320,300
Closed -$4.32M – 3935
2025
Q1 		$4.32M Sell
320,300
-50,900
-14% -$867K 0.01% 1525
2024
Q4 		$7.12M Buy
371,200
+311,600
+523% +$6.78M 0.01% 1223
2024
Q3 		$1.36M Sell
59,600
-188,000
-76% -$3.07M ﹤0.01% 2262
2024
Q2 		$3.22M Sell
247,600
-14,100
-5% -$195K 0.01% 1573
2024
Q1 		$4.58M Buy
261,700
+248,300
+1,853% +$4.81M 0.01% 1467
2023
Q4 		$292K Sell
13,400
-51,800
-79% -$818K ﹤0.01% 3000
2023
Q3 		$1M Sell
65,200
-10,800
-14% -$206K ﹤0.01% 2295
2023
Q2 		$1.81M Buy
76,000
+40,200
+112% +$1.03M ﹤0.01% 2067
2023
Q1 		$911K Buy
+35,800
New +$1.15M ﹤0.01% 2540
2022
Q4 		– Sell
-101,600
Closed -$2.08M – 4448
2022
Q3 		$2.08M Buy
+101,600
New +$1.83M ﹤0.01% 1976
2021
Q2 		– Sell
-13,240
Closed -$221K – 3802
2021
Q1 		$221K Sell
13,240
-40,162
-75% -$752K ﹤0.01% 3124
2020
Q4 		$878K Buy
53,402
+48,361
+959% +$729K ﹤0.01% 2566
2020
Q3 		$59K Sell
5,041
-32,007
-86% -$477K ﹤0.01% 3260
2020
Q2 		$617K Sell
37,048
-3,227
-8% -$36.6K ﹤0.01% 2791
2020
Q1 		$270K Buy
40,275
+9,339
+30% +$109K ﹤0.01% 3013
2019
Q4 		$223K Buy
30,936
+17,355
+128% +$178K ﹤0.01% 3166
2019
Q3 		$149K Buy
13,581
+1,614
+13% +$35.7K ﹤0.01% 3210
2019
Q2 		$368K Buy
11,967
+2,307
+24% +$92.6K ﹤0.01% 3102
2019
Q1 		$404K Sell
9,660
-793
-8% -$35.9K ﹤0.01% 3003
2018
Q4 		$475K Buy
+10,453
New +$605K ﹤0.01% 2882
2018
Q2 		– Sell
-2,048
Closed -$215K – 3554
2018
Q1 		$215K Sell
2,048
-3,419
-63% -$371K ﹤0.01% 3166
2017
Q4 		$855K Buy
+5,467
New +$697K ﹤0.01% 2725
2017
Q1 		– Sell
-706
Closed -$53K – 3426
2016
Q4 		$53K Buy
706
+538
+320% +$56.2K ﹤0.01% 3161
2016
Q3 		$19K Buy
168
+100
+147% +$11.2K ﹤0.01% 3289
2016
Q2 		$6K Buy
+68
New +$8.34K ﹤0.01% 3297

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Renaissance Technologies's VRDN Position: Q2 2026 in Review

Renaissance Technologies increased its Viridian Therapeutics (VRDN) stake by 278% in Q2 2026, buying an estimated $9.11M and bringing the position to 768,600 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #876.

Renaissance Technologies first reported a position in VRDN in Q2 2016 and has held it in 27 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Renaissance Technologies held 768,600 shares of Viridian Therapeutics worth $14.1M as of Q2 2026.
  • Renaissance Technologies bought 565,500 Viridian Therapeutics shares in Q2 2026, an estimated $9.11M.
  • Viridian Therapeutics made up 0.02% of Renaissance Technologies's portfolio in Q2 2026, its #876 holding.
  • Renaissance Technologies first reported a position in Viridian Therapeutics in Q2 2016 and has held it in 27 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.